Current status of biomarkers in head and neck cancer.
As our understanding of HNSCC increases so has biomarker development. HPV16 integration is a significant marker of favorable prognosis and response to therapy for HNSCC. EGFR-amplification and overexpression is a poor-prognostic indicator. For premalignant lesions, LOH of 3p&9p21 loci confers an elevated risk of malignant transformation. As molecular targets are identified, these will be candidates for biomarkers for detection, diagnosis, prognosis, and therapy. Validation of these biomarkers requires demonstration of independence of significance beyond known biomarkers.
Chang
Steven S
SS
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-0910, USA.
Califano
Joseph
J
D015415:Biomarkers / Q000032:analysis; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000473:pathology / Q000821:virology; D002471:Cell Transformation, Neoplastic; D066246:ErbB Receptors / Q000378:metabolism; D006258:Head and Neck Neoplasms / Q000235:genetics* / Q000473:pathology* / Q000821:virology; D006801:Humans; D019656:Loss of Heterozygosity; D027383:Papillomaviridae / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000821:virology; D011230:Precancerous Conditions / Q000473:pathology
D015415:Biomarkers; D066246:ErbB Receptors